Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Allergy. European Journal of Allergy and Clinical Immunology

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/all.13138PMID 28152201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial

  2017cited by this paper
• Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.

  2016cited by this paper
• Monitoring Allergen Immunotherapy Effects by Microarray

  2016cited by this paper
• Toward precision medicine and health: Opportunities and challenges in allergic diseases.

  2016cited by this paper
• Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy.

  2016cited by this paper
• Initial immunological changes as predictors for house dust mite immunotherapy response

  2015cited by this paper
• In vivo diagnosis of allergic diseases—allergen provocation tests

  2015cited by this paper
• Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs.

  2015cited by this paper
• Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a.

  2015cited by this paper
• A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study

  2015cited by this paper
• Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen‐specific basophil response; a real‐life, nonrandomized controlled study

  2015cited by this paper
• Advances in allergen immunotherapy: Aiming for complete tolerance to allergens

  2015cited by this paper
• Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens

  2015cited by this paper
• Local and systemic effects of cat allergen nasal provocation

  2015cited by this paper
• Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy

  2015cited by this paper
• International consensus on allergy immunotherapy.

  2015cited by this paper
• IL-10-overexpressing B cells regulate innate and adaptive immune responses.

  2015cited by this paper
• Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.

  2015cited by this paper
• Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge

  2015cited by this paper
• Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response.

  2015cited by this paper
• Clinical and cytokine responses to house dust mite sublingual immunotherapy.

  2015cited by this paper
• The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

  2015cited by this paper
• Cytokine Responses to Specific Immunotherapy in House Dust Mite-Induced Allergic Rhinitis Patients

  2015cited by this paper
• Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper.

  2014cited by this paper
• Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens.

  2014cited by this paper
• Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.

  2014cited by this paper
• Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip.

  2014cited by this paper
• Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy

  2014cited by this paper
• Allergen immunotherapy: clinical outcomes assessment.

  2014cited by this paper
• Phase I/II study of oral immunotherapy with Cry j1-galactomannan conjugate for Japanese cedar pollinosis.

  2014cited by this paper
• A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis

  2014cited by this paper
• Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy.

  2014cited by this paper
• An update on allergen immunotherapy and asthma

  2014cited by this paper
• Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).

  2014cited by this paper
• Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response?

  2014cited by this paper
• Predictive Factors for Clinical Response to Allergy Immunotherapy in Children with Asthma and Rhinitis

  2014cited by this paper
• Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy.

  2014cited by this paper
• Evaluation of Clinical and Immunological Responses: A 2-Year Follow-Up Study in Children with Allergic Rhinitis due to House Dust Mite

  2013cited by this paper
• Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

  2013cited by this paper
• Allergen immunotherapy and tolerance.

  2013cited by this paper
• Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.

  2013cited by this paper
• IL-35+ Regulatory T Cells Suppress Grass Pollen-Driven Th2 Responses and Are Induced Following Grass Pollen-Specific Sublingual Immunotherapy

  2013cited by this paper
• Depigmented–polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients

  2013cited by this paper
• Fast onset of action of sublingual immunotherapy in house dust mite‐induced allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled trial

  2013cited by this paper
• Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber

  2013cited by this paper
• Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

  2013cited by this paper
• Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?

  2013cited by this paper
• Effect of Japanese cedar specific immunotherapy on allergen-specific T(H)2 cells in peripheral blood.

  2013cited by this paper
• Local Nasal 'Protective' Immunoglobulin G4 (IgG4) Responses in Nasal Fluid Following Grass Pollen Sublingual Immunotherapy

  2013cited by this paper
• Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.

  2013cited by this paper
• Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy

  2013cited by this paper
• Kinetics, cross‐reactivity, and specificity of Bet v 1‐specific IgG4 antibodies induced by immunotherapy with birch pollen

  2013cited by this paper
• Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy.

  2013cited by this paper
• Enhancement of the Frequency and Function of IL-10-Secreting Type I T Regulatory Cells after 1 Year of Cluster Allergen-Specific Immunotherapy

  2012cited by this paper
• Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis

  2012cited by this paper
• EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy

  2012cited by this paper
• Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes.

  2012cited by this paper
• High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.

  2012cited by this paper
• Allergen‐specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy

  2012cited by this paper
• Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections.

  2012cited by this paper
• Immune regulatory function of B cells.

  2012cited by this paper
• Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy

  2012cited by this paper
• Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes.

  2012cited by this paper
• Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study

  2012cited by this paper
• Real time eosinophil and neutrophil migration in non asthmatic and asthmatic human volunteers

  2012cited by this paper
• Analyzing histamine release by flow cytometry (HistaFlow): a novel instrument to study the degranulation patterns of basophils.

  2012cited by this paper
• Desensitization Effect of Preseasonal Seven-Injection Allergoid Immunotherapy with Olive Pollen on Basophil Activation: The Efficacy of Olive Pollen-Specific Preseasonal Allergoid Immunotherapy on Basophils

  2012cited by this paper
• SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

  2012cited by this paper
• A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy.

  2012cited by this paper
• Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.

  2012cited by this paper
• Dendritic cells modifi cation during sublingual immunotherapy in children with allergic symptoms to house dust mites

  2011cited by this paper
• Effects of allergen-specific immunotherapy on functions of helper and regulatory T cells in patients with seasonal allergic rhinitis.

  2011cited by this paper
• House dust mite sublingual immunotherapy: results of a US trial.

  2011cited by this paper
• The role of basophils in the pathogenesis of allergic disease

  2011cited by this paper
• Mechanisms of immunotherapy to aeroallergens

  2011cited by this paper
• Mechanism of immunoglobulin G4 Fab-arm exchange.

  2011cited by this paper
• Clinico‐immunological changes post‐immunotherapy with Periplaneta americana

  2011cited by this paper
• Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

  2011cited by this paper
• International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.

  2011cited by this paper
• Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults.

  2011cited by this paper
• Sublingual immunotherapy in allergic rhinitis

  2011cited by this paper
• Systematic reviews of sublingual immunotherapy (SLIT)

  2011cited by this paper
• Diagnostic tools in Rhinology EAACI position paper

  2011cited by this paper
• Serum IL-9 levels and sublingual immunotherapy: preliminary report.

  2011cited by this paper
• Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta‐analysis

  2011cited by this paper
• Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.

  2011cited by this paper
• A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.

  2011cited by this paper
• Immune response to sublingual immunotherapy in children allergic to mites.

  2011cited by this paper
• Changes in basophil activation during grass‐pollen sublingual immunotherapy do not correlate with clinical efficacy

  2011cited by this paper
• Effect of One-Year Subcutaneous and Sublingual Immunotherapy on Clinical and Laboratory Parameters in Children with Rhinitis and Asthma: A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy Study

  2011cited by this paper
• Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.

  2011cited by this paper
• Sublingual immunotherapy for treating allergic conjunctivitis.

  2011cited by this paper
• Clinical outcome and IL‐17, IL‐23, IL‐27 and FOXP3 expression in peripheral blood mononuclear cells of pollen‐allergic children during sublingual immunotherapy

  2010cited by this paper
• Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis.

  2010cited by this paper
• Functional regulatory T cells and allergen immunotherapy

  2010cited by this paper
• Allergen‐specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression

  2010cited by this paper
• [Allergic rhinitis and its impact on asthma].

  2010cited by this paper
• Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial.

  2010cited by this paper
• Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes

  2010cited by this paper
• Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3‐expressing cells and elevated allergen‐specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E‐facilitated allergen binding to B cells

  2010cited by this paper

• Distinct treatment response trajectories to allergen immunotherapy in allergic asthma and rhinitis: Insights from a multicenter study in routine clinical practice

  2026cites this paper
• A prospective cohort study of ultra-rush subcutaneous immunotherapy in dust mite-induced allergic rhinitis

  2026cites this paper
• Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm

  2025cites this paper
• Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

  2025influential citation
• Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes

  2025cites this paper
• A one‐year efficacy assessment of subcutaneous immunotherapy in dust mite allergic rhinitis patients based on clinical symptoms and objective biomarkers

  2025cites this paper
• Indicación de vacunación-inmunoterapia en las enfermedades alérgicas

  2025cites this paper
• Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis.

  2025cites this paper
• Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial

  2025cites this paper
• Tumor necrosis factor receptor 2 in allergen tolerance: a perspective view

  2025cites this paper
• Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial

  2025cites this paper
• Changes in IgE, IgE Bet v 1 and IgG4 levels after successful allergen-specific therapy with a sublingual birch preparation

  2025cites this paper
• Efficacy of the sublingual tablets for allergen-specific immunotherapy «Antypollin» in the treatment of allergic rhinitis caused by birch pollen

  2025cites this paper
• Improvement of the therapeutic management of allergic patients in Europe – An expert think tank's position paper on allergen immunotherapy

  2025cites this paper
• BDNF as a biomarker for evaluating clinical response in allergic rhinitis patients undergoing allergen-specific immunotherapy

  2025cites this paper
• Systemtherapie bei allergologischen Erkrankungen

  2025cites this paper
• AI-Driven Biomarker Discovery and Personalized Allergy Treatment: Utilizing Machine Learning and NGS

  2025cites this paper
• Allergen Immunotherapy: Pitfalls, Perks and Unexpected Allies

  2025cites this paper
• T Cell Exhaustion in Allergic Diseases and Allergen Immunotherapy: A Novel Biomarker?

  2025cites this paper
• Molecular allergy diagnosis enabling personalized medicine.

  2025cites this paper
• Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study

  2025cites this paper
• Pathological IgE Production in Inborn Errors of Immunity and Beyond

  2025cites this paper
• Multiomics approach to evaluating personalized biomarkers of allergen immunotherapy.

  2025cites this paper
• Subcutaneous House Dust Mite Immunotherapy Effectiveness and Safety in a Paediatric Population: A Prospective Real-Life Study

  2025cites this paper
• Vaccines and adjuvants in allergen specific immunotherapy: current status and future directions

  2025cites this paper
• Intranasal Immunotherapy with Allergen-Loaded Extracellular Vesicles from Mast Cells Alleviates Allergic Asthma Inflammation in a Murine Model

  2025cites this paper
• Role of IgG4 Antibodies in Human Health and Disease

  2025cites this paper
• IgG4-Rich Lesions Associated With Intranasal Drug Use Can Mimic IgG4-Related Disease.

  2024cites this paper
• Evaluation of the Correlation Between Nasal Secretion ECP-MPO Test Papers and Immune Markers in Subcutaneous Immunotherapy of Dust Mites

  2024cites this paper
• Reducing the solubility of the major birch pollen allergen Bet v 1 by particle-loading mitigates Th2 responses.

  2024cites this paper
• Recent developments in immunotherapy approaches for allergic rhinitis

  2024cites this paper
• V Brazilian Consensus on Rhinitis – 2024

  2024cites this paper
• On the role of antibody affinity and avidity in the IgE‐mediated allergic response

  2024cites this paper
• [Molecular allergen IgE tests show neosensitizaions occurring during house dust mite specific immunotherapy].

  2024cites this paper
• Consistent efficacy and safety of sublingual immunotherapy tablets across allergens and geographic regions.

  2024cites this paper
• Effectiveness of allergen-specific immunotherapy in children with bronchial asthma sensitized to house dust mites

  2024cites this paper
• Allergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)

  2024cites this paper
• Allergen immunotherapy in asthma.

  2024cites this paper
• Development and validation of a health practitioner survey on ocular allergy

  2024cites this paper
• Oral immunotherapy with enteric-coated capsules for allergic rhinitis caused by house dust mites

  2024cites this paper
• Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy

  2024cites this paper
• Features of the formation of early immunological tolerance during immunotherapy with allergens in patients with allergic rhinitis.

  2024cites this paper
• [Allergen-specific immunotherapy : A brief overview in association with allergic conjunctivitis].

  2024cites this paper
• Novel adjuvants in allergen-specific immunotherapy: where do we stand?

  2024cites this paper
• Predicting allergen immunotherapy efficacy based on early maintenance phase response in routine clinical practice

  2024cites this paper
• Evaluation of the Cytokine Response Induced by Specific Allergen Immunotherapy in Patients with Vespa velutina Anaphylaxis

  2024cites this paper
• A Modern Approach to Clinical Outcome Assessment in Allergy Management: Advantages of Allergen Exposure Chambers

  2024cites this paper
• Intratonsillar Immunotherapy: A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis

  2024cites this paper
• Short‐course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy

  2024cites this paper
• IgE versus IgG and IgA: Differential roles of allergen‐specific antibodies in sensitization, tolerization, and treatment of allergies

  2024cites this paper
• Pathogenic and Nonpathogenic Antibody Responses in Allergic Diseases

  2024cites this paper
• Efficacy and safety of subcutaneous immunotherapy combined with omalizumab in children with dust mite-induced asthma

  2024cites this paper
• [Research progress of immune cell markers in allergic rhinitis for the evaluation of allergen immunotherapy].

  2024cites this paper
• Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet

  2023cites this paper
• Clinical endpoints in allergen immunotherapy: State of the art 2022

  2023cites this paper
• Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling.

  2023cites this paper
• Serum exosomal miR-146a-3p associates with disease severity and efficacy of sublingual immunotherapy in allergic rhinitis.

  2023cites this paper
• Deciphering Differential Behavior of Immune Responses as the Foundation for Precision Dosing in Allergen Immunotherapy

  2023cites this paper
• T-helper-2 cells and atopic disease: lessons learnt from inborn errors of immunity.

  2023cites this paper
• Relationship between Food Allergy and Endotoxin Concentration and the Toleration Status at 2 Years: The Japan Environment and Children’s Study

  2023cites this paper
• Mechanisms and predictive biomarkers of allergen immunotherapy in the clinic.

  2023cites this paper
• Allergen immunotherapy in allergic asthma

  2023cites this paper
• International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

  2023cites this paper
• Molecular Aspects of Allergen-Specific Immunotherapy in Patients with Seasonal Allergic Rhinitis

  2023influential citation
• Allergen-specific immunotherapy and evidence: A European regulatory perspective

  2023cites this paper
• Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation

  2023influential citation
• PREVENTION IS BETTER THAN CURE: IMPACT OF ALLERGEN IMMUNOTHERAPY ON THE PROGRESSION OF AIRWAY DISEASE.

  2023cites this paper
• Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells

  2023cites this paper
• KAAACI Guidelines for Allergen Immunotherapy

  2023cites this paper
• On the role of antibody affinity in the IgE mediated allergic response

  2023cites this paper
• Validation of AI-based software for objectification of conjunctival provocation test

  2023cites this paper
• Der p 1-specific Treg and Breg cells in allergen immunotherapy and mechanism of immune tolerance

  2023cites this paper
• Predicting the therapeutic efficacy of AIT for asthma using clinical characteristics, serum allergen detection metrics, and machine learning techniques

  2023cites this paper
• Potential Effects of AIT on Nonspecific Allergic Immune Responses or Symptoms

  2023cites this paper
• Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper

  2023cites this paper
• The early-phase transcriptome and the clinical efficacy analysis in three modes of subcutaneous immunotherapy for allergic rhinitis

  2023cites this paper
• [Value of allergen nasal provocation test in assessment of the efficacy of house dust mites specific immunotherapy].

  2023cites this paper
• Natural human Bet v 1‐specific IgG antibodies recognize non‐conformational epitopes whereas IgE reacts with conformational epitopes

  2023cites this paper
• B cells: The many facets of B cells in allergic diseases.

  2023cites this paper
• Allergen immunotherapy: progress and future outlook

  2023influential citation
• Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation

  2023cites this paper
• EAACI Molecular Allergology User's Guide 2.0

  2023cites this paper
• Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization

  2023cites this paper
• Clinical and Experimental Treatment of Allergic Asthma with an Emphasis on Allergen Immunotherapy and its Mechanisms.

  2023cites this paper
• Multimorbidity of Allergic Conditions in Urban Citizens of Southern China: A Real-World Cross-Sectional Study

  2023influential citation
• Comparison of allergen immunotherapy practice patterns in inhalant allergies in the United States of America and Europe: Similarities and differences 2023

  2023cites this paper
• Vaccination against infectious agents and allergen-specific immunotherapy: A critical analysis

  2023cites this paper
• Effects of allergen immunotherapy on follicular regulatory T cells

  2023cites this paper
• Epigenetics and precision medicine in allergic diseases

  2022cites this paper
• Capítulo 2. Diagnóstico molecular

  2022cites this paper
• Allergen immunotherapy for respiratory allergies in clinical practice: A comprehensive review.

  2022cites this paper
• Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update

  2022cites this paper
• Monitoring of molecular profiling of allergen-antibody responses in HDM-immunotherapy patients

  2022cites this paper
• 遺伝子型に基づく鼻副鼻腔疾患の治療戦略

  2022cites this paper
• How the Immune System Responds to Allergy Immunotherapy

  2022cites this paper
• Extrapolating Evidence Based Medicine of AIT into Clinical Practice in the US.

  2022cites this paper
• Immunogenicity of a novel anti-allergic vaccine based on house dust mite purified allergens and a combination adjuvant in a murine prophylactic model

  2022influential citation
• Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-β, in dogs with atopic dermatitis.

  2022cites this paper
• 111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases

  2022cites this paper
• Краткие сообщения Short СОДЕРЖАНИЕ PD-1 И PD-L1 ЛИМФОЦИТОВ ПЕРИФЕРИЧЕСКОЙ КРОВИ У ЛИЦ С ПЫЛЬЦЕВОЙ СЕНСИБИЛИЗАЦИЕЙ ДО И ПОСЛЕ ПРОВЕДЕНИЯ АЛЛЕРГЕН-СПЕЦИФИЧЕСКОЙ ИММУНОТЕРАПИИ

  2022cites this paper